Whether the third-generation targeted anticancer drug Tagrisso will be able to receive reimbursement expansions in 2023 is gaining attention

According to industry sources, AstraZeneca Korea submitted additional supplementary data to extend reimbursement of its EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment to the first line at the end of last year after submitting its application in October last year.

Therefore, whether Tagrisso’s reimbursement application will pass the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee review and be finally extended to the first line after 4 years remains to be seen.

Tagrisso, w